The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Open accessAbstract
BACKGROUND: Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving standard therapy. METHODS: In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day 1 and at weeks 2, 24, 26, and 52, with or without a dose at week 50) or placebo. All patients received standard therapy with mycophenolate mofetil, along with oral prednisone at a target dose of 7.5 mg per day by week 12 and 5 mg per day by week 24. The primary end point was a complete renal response at week 76, defined by a urinary protein-to-creatinine ratio of less than 0.5 (with protein and creatinine both measured in milligrams), an estimated glomerular filtration rate of at least 85% of the baseline value, and no intercurrent event (i.e., rescue therapy, treatment failure, death, or early trial withdrawal). Key secondary end points at week 76 included a complete renal response with a prednisone dose of 7.5 mg per day or lower between weeks 64 and 76 and a urinary protein-to-creatinine ratio lower than 0.8 without an intercurrent event. RESULTS: A total of 271 patients underwent randomization; 135 were assigned to the obinutuzumab group (combined dose schedules) and 136 to the placebo group. A complete renal response at week 76 was observed in 46.4% of the patients in the obinutuzumab group and 33.1% of those in the placebo group (adjusted difference, 13.4 percentage points; 95% confidence interval [CI], 2.0 to 24.8; P = 0.02). A complete renal response at week 76 with a prednisone dose of 7.5 mg per day or lower between weeks 64 and 76 was observed in more patients in the obinutuzumab group than in the placebo group (42.7% vs. 30.9%; adjusted difference, 11.9 percentage points; 95% CI, 0.6 to 23.2; P = 0.04), and a urinary protein-to-creatinine ratio lower than 0.8 without an intercurrent event was more common with obinutuzumab than with placebo (55.5% vs. 41.9%; adjusted difference, 13.7 percentage points; 95% CI, 2.0 to 25.4; P = 0.02). No unexpected safety signals were identified. More serious adverse events, mainly infections and events related to coronavirus disease 2019, occurred with obinutuzumab than with placebo. CONCLUSIONS: Among adults with active lupus nephritis, obinutuzumab plus standard therapy was more efficacious than standard therapy alone in providing a complete renal response. (Funded by F. Hoffmann-La Roche; REGENCY ClinicalTrials.gov number, NCT04221477.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey‐Goldman, R., Smolen, J. S., Wofsy, D., Boumpas, D. T., Kamen, D. L., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40930 · Cited by 2,677
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited
Weening, J. J., D’Agati, V. D., Schwartz, M. M., Seshan, S. V., Alpers, C. E., Appel, G. B., Balow, J. E., Bruijn, J. A., Cook, T., Ferrario, F., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000108969.21691.5d · Cited by 2,008
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., de la Serna, J., Dilhuydy, M.-S., Illmer, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313984 · Cited by 1,518
Rovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461
Self-citationCD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
Müller, F., Taubmann, J., Bucci, L., Wilhelm, A., Bergmann, C., Völkl, S., Aigner, M., Rothe, T., Minopoulou, I., Tur, C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2308917 · Cited by 1,095
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Furie, R., Rovin, B. H., Houssiau, F., Malvar, A., Teng, Y. K. O., Contreras, G., Amoura, Z., Yu, X., Mok, C.-C., Santiago, M. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001180 · Cited by 1,032
Self-citationMössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Anders, H.-J., Saxena, R., Zhao, M.-H., Parodis, I., Salmon, J. E., & Mohan, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0141-9 · Cited by 958
Rovin, B. H., Teng, Y. K. O., Ginzler, E. M., Arriens, C., Caster, D. J., Romero-Diaz, J., Gibson, K., Kaplan, J., Lisk, L., Navarra, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00578-x · Cited by 635
Self-citationLevey, A. S., Gansevoort, R. T., Coresh, J., Inker, L. A., Heerspink, H. L., Grams, M. E., Greene, T., Tighiouart, H., Matsushita, K., Ballew, S. H., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.06.009 · Cited by 591
KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS
Rovin, B. H., Ayoub, I. M., Chan, T. M., Liu, Z.-H., Mejía-Vilet, J. M., & Floege, J. (2024) · Kidney International · doi:10.1016/j.kint.2023.09.002 · Cited by 517
Self-citationFurie, R. A., Aroca, G., Cascino, M. D., Garg, J. P., Rovin, B. H., Alvarez, A., Fragoso-Loyo, H., Zuta-Santillan, E., Schindler, T., Brunetta, P., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220920 · Cited by 459
Self-citationHerter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1182 · Cited by 366
Dall'Era, M., Cisternas, M. G., Smilek, D. E., Straub, L., Houssiau, F. A., Cervera, R., Rovin, B. H., & Mackay, M. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39026 · Cited by 329
Self-citationBarber, R. M., Sorensen, R. J. D., Pigott, D. M., Bisignano, C., Carter, A., Amlag, J. O., Collins, J. K., Abbafati, C., Adolph, C., Allorant, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00484-6 · Cited by 298
Alduaij, W., Ivanov, A., Honeychurch, J., Cheadle, E. J., Potluri, S., Lim, S. H., Shimada, K., Chan, C. H. T., Tutt, A., Beers, S. A., et al. (2011) · Blood · doi:10.1182/blood-2010-07-296913 · Cited by 294
Tamirou, F., Lauwerys, B. R., Dall'Era, M., Mackay, M., Rovin, B., Cervera, R., & Houssiau, F. A. (2015) · Lupus Science & Medicine · doi:10.1136/lupus-2015-000123 · Cited by 242
Self-citationBCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Wang, W., He, S., Zhang, W., Zhang, H., DeStefano, V. M., Wada, M., Pinz, K., Deener, G., Shah, D., Hagag, N., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2024-225785 · Cited by 233
Reddy, V., Klein, C., Isenberg, D. A., Glennie, M. J., Cambridge, G., Cragg, M. S., & Leandro, M. J. (2017) · Rheumatology · doi:10.1093/rheumatology/kex067 · Cited by 205
Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis
Gomez Mendez, L. M., Cascino, M. D., Garg, J., Katsumoto, T. R., Brakeman, P., Dall’Era, M., Looney, R. J., Rovin, B., Dragone, L., & Brunetta, P. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01070118 · Cited by 188
Self-citationCD19-CAR T-cell therapy induces deep tissue depletion of B cells
Tur, C., Eckstein, M., Velden, J., Rauber, S., Bergmann, C., Auth, J., Bucci, L., Corte, G., Hagen, M., Wirsching, A., et al. (2025) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2024-226142 · Cited by 187
Brill, L., Rechtman, A., Zveik, O., Haham, N., Oiknine-Djian, E., Wolf, D. G., Levin, N., Raposo, C., & Vaknin-Dembinsky, A. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3599 · Cited by 172
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
Inker, L. A., Collier, W., Greene, T., Miao, S., Chaudhari, J., Appel, G. B., Badve, S. V., Caravaca-Fontán, F., Del Vecchio, L., Floege, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02418-0 · Cited by 171
Honeychurch, J., Alduaij, W., Azizyan, M., Cheadle, E. J., Pelicano, H., Ivanov, A., Huang, P., Cragg, M. S., & Illidge, T. (2012) · Blood · doi:10.1182/blood-2011-12-395541 · Cited by 144
Curtis, J. R., Johnson, S. R., Anthony, D. D., Arasaratnam, R. J., Baden, L. R., Bass, A. R., Calabrese, C. M., Gravallese, E. M., Harpaz, R., Kroger, A. T., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42372 · Cited by 139
Lupus nephritis-related chronic kidney disease
Lichtnekert, J., & Anders, H. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01158-w · Cited by 110
Pathogenic cellular and molecular mediators in lupus nephritis
Mohan, C., Zhang, T., & Putterman, C. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00722-z · Cited by 105
Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients
Liebers, N., Speer, C., Benning, L., Bruch, P., Kraemer, I., Meißner, J., Schnitzler, P., Kräusslich, H., Dreger, P., Müller‐Tidow, C., et al. (2021) · Blood · doi:10.1182/blood.2021013445 · Cited by 93
Mackay, M. C., Dall’Era, M., Fishbein, J. S., KALUNIAN, K. C., LESSER, M. L., Sánchez‐Guerrero, J., Levy, D. M., Silverman, E. D., Petri, M., Arriens, C., et al. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40724 · Cited by 74
Self-citationMeant to B: B cells as a therapeutic target in systemic lupus erythematosus
Atisha‐Fregoso, Y., Toz, B., & Diamond, B. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149095 · Cited by 73
Rovin, B. H., Furie, R. A., Terres, J. A. R., Giang, S., Schindler, T. H., Turchetta, A., Garg, J. P., Pendergraft, W. F., & Malvar, A. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42734 · Cited by 60
Self-citationObinutuzumab in the treatment of B-cell malignancies: a comprehensive review
Davies, A. J., Kater, A. P., Sharman, J. P., Stilgenbauer, S., Vitolo, U., Klein, C., Parreira, J. M., & Salles, G. A. (2022) · Future Oncology · doi:10.2217/fon-2022-0112 · Cited by 46
Januel, É., Hajage, D., Labauge, P. M., Maillart, É., Seze, J. D., Zéphir, H., Pelletier, J., Guilloton, L., Bensa, C., Heinzlef, O., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.19766 · Cited by 39
Anderson, E., Powell, M. D., Yang, E., Kar, A., Leung, T. M., Sison, C. P., Steinberg, R., Mims, R., Choudhury, A., Espinosa, C., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.180750 · Cited by 13
Pinto, A., Caltagirone, M., Battista, M., Gazzoli, G. C., Patti, C., Pennese, E., Lorenzo, S. D., Pavone, V., Merli, M., Chiarenza, A., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19661 · Cited by 6
Metadata
- Authors
- Furie, R. A., Rovin, B. H., Garg, J. P., Santiago, M. B., Aroca-Martínez, G., Zuta Santillán, A. E., Alvarez, D., Navarro Sandoval, C., Lila, A. M., Tumlin, J. A., Saxena, A., Irazoque Palazuelos, F., Raghu, H., Yoo, B., Hassan, I., Martins, E., Sehgal, H., Kirchner, P., Ross Terres, J., Omachi, T. A., Schindler, T., Pendergraft, W. F., & Malvar, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-04-17
- Volume
- 392
- Issue
- 15
- Pages
- 1471-1483
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4407259591
- Cited by
- 260
- References
- 36
- FWCI
- 164.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.